Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether the anabolic potentials of insulin may be used to reverse the catabolic effects of hemodialysis in non-diabetic patients with end-stage renal failure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: Insulin; Insulin Aspart; Insulin, Globin Zinc; Mitogens

Criteria

Inclusion Criteria:

• > 18 years

• stable patients on maintenance hemodialysis for > 3 months

• well-functioning arteriovenous (AV) shunt with recirculation < 5%

• informed consent

Exclusion Criteria:

• diabetes mellitus

• body mass index < 18.5 kg/m2 or > 30 kg/m2

• malnutrition (subjective global assessment (SGA) score C)

• malignancy

• use of immunosuppressive drugs including glucocorticosteroids

• severe infectious disease < 4 weeks

• pregnancy

Exclusion Criteria during the study:

• myocardial infarction or arrythmia with hemodynamic derangements

• permanent thrombosis in the arteriovenous (AV) shunt

• severe infectious disease

• renal transplantation